A New Immune Player in Type 1 Diabetes: What TIGIT+ B Cells Tell Us

For years, scientists focused on TIGIT as an immune checkpoint found on T cells and natural killer cells—specialized immune defenders. But recent research has revealed that TIGIT also appears on certain B cells, a different class of immune cell. What makes this discovery important is what these TIGIT+ B cells appear to do: instead of attacking the body, they seem to help regulate and calm down immune responses.

Think of TIGIT+ B cells as immune mediators. They don't start fights; they help referee them. This regulatory role makes them fundamentally different from many other B cells, which are typically part of the offensive immune army.

Scientists have identified several ways that TIGIT+ B cells appear to maintain immune balance. First, they release anti-inflammatory cytokines—chemical signals that tell other immune cells to calm down. Second, they modify how antigen-presenting cells behave; these are the cells that show the immune system what targets to attack. By influencing these messengers, TIGIT+ B cells can reshape which cells get activated.

TIGIT+ B cells also appear to communicate directly with regulatory T cells, another type of immune cell known for keeping autoimmunity in check. Through this two-way conversation, both cell types may work together to maintain immune tolerance—the body's ability to distinguish between harmful invaders and its own healthy tissues.

Type 1 diabetes is an autoimmune disease where the immune system mistakenly attacks insulin-producing cells in the pancreas. This is where TIGIT+ B cells become particularly interesting: research shows these regulatory cells are present in Type 1 diabetes and appear to have activity that limits disease progression.

The evidence in Type 1 diabetes is notably strong compared to other autoimmune conditions. Researchers have direct experimental findings showing that TIGIT+ B cells display genuine regulatory activity in this disease context, rather than indirect or inferred evidence. This suggests TIGIT+ B cells may be a natural brake the body uses to try to control its own autoimmune response.

Because TIGIT+ B cells appear to have protective effects in Type 1 diabetes, researchers are exploring whether therapies could harness or enhance this activity. Strategies might involve boosting these cells directly or amplifying the TIGIT signaling pathways they use to regulate immunity.

This research is still in early stages, however. Scientists are working to understand TIGIT+ B cell biology more completely before moving toward clinical applications. Key challenges include learning exactly which signals activate these cells, how to reliably expand them, and how to ensure any treatment approach is safe and effective over the long term.

While TIGIT+ B cells represent a promising avenue of research in Type 1 diabetes, important questions remain unanswered. Researchers are still learning why these cells are sometimes sufficient to limit disease progression and why, in other cases, autoimmunity proceeds despite their presence. Understanding these variations could reveal what distinguishes people who naturally control their autoimmunity better from those who don't.

The journey from basic research to patient treatment typically takes years. Right now, TIGIT+ B cells offer valuable clues about how the immune system's natural regulatory systems work. As that understanding deepens, it may eventually inform new therapeutic strategies—but that clinical application remains on the horizon, not yet within reach.

Source: Frontiers in immunology. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.